• Explore /
  • Poster
  • / Preliminary results of a phase 1 study of sea-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

Preliminary results of a phase 1 study of sea-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

Abstract Video & Slides Poster

Authors

David Bajor

David Lawrence Bajor

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

David Lawrence Bajor , Martin Gutierrez , Gina M. Vaccaro , Ashiq Masood , Ursa Brown-Glaberman , Juneko E. Grilley-Olson , Hedy L. Kindler , Mark Zalupski , Elisabeth I. Heath , Sarina Anne Piha-Paul , Peigen Zhou , Hailing Lu , Sahar Ansari , Jonathan Hayman , Michael W. Schmitt , Andrew L. Coveler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02376699

DOI

10.1200/JCO.2022.40.4_suppl.559

Abstract #

559

Poster Bd #

G10

Abstract Disclosures

Similar Posters

First Author: Andrew L. Coveler

First Author: David Lawrence Bajor

First Author: Andrew L. Coveler

Poster

2017 Gastrointestinal Cancers Symposium

Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer.

Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer.

First Author: Andrea Wang-Gillam